Business
Novavax Announces Leadership Updates
- Gale E. Smith, Ph.D., Chief Scientist, promoted to Senior Vice President - Troy Morgan, J.D., appointed Chief Compliance Officer - Greg Covino to step down
About this update from Novavax, Inc.
[{"type":"text","content":"- Gale E. Smith, Ph.D., Chief Scientist, promoted to Senior Vice President\n - Troy Morgan, J.D., appointed Chief Compliance Officer\n - Greg Covino to step down as Chief Financial Officer, remain with company as executive adviser\n\n\nGAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as Chief Financial Officer (CFO) and will take on a new role as executive adviser to the company. \nRecognized as a pioneer in vaccine research, Dr. Smith is the senior inventor of the insect cell technology that serves as the basis of Novavax' scientific platform and is used broadly by the pharmaceutical industry, as well as on the company's vaccine patents for respiratory syncytial virus (RSV), Ebola, influenza and coronavirus vaccines, including COVID-19. He is widely published and holds numerous patents for the baculovirus-insect cell expression system as well as seasonal influenza vaccines and adjuvants. Since joining Novavax in January 2004, he has overseen discovery and pre-clinical research and leads vaccine technology development. \n\"Dr. Smith's scientific insights and leadership are an invaluable asset to Novavax and have already delivered vaccines that protect the health of millions worldwide,\" said Gregory M. Glenn, M.D., President of Research and Development, Novavax. \"This well-deserved promotion reflects not only his major contributions in creating our COVID-19 vaccine candidate, but well over a decade of dedication to improving our technology platform.\" \nMr. Morgan joins Novavax from EMD Serono, Inc., where he was Chief Compliance Officer, responsible for building a global corporate compliance program that supported a broad range of therapies. Previously, he served in senior leadership roles at Merck KGaA, Sanofi, and Biogen. At the Biogen spinout Bioverativ, he was responsible for the development, implementation and management of the global compliance program. He holds a Master of Laws from Pepperdine University, Juris D...